Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase I/II study of SHR-8203 injection in participants with advanced solid tumors
CTR20263142Phase 2Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Aug 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-8203 in Nonhematologic neoplasms, sponsored by Beijing Shengdi Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
SHR-8203
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263142.